Loading...
This week, NEJM Journal Watch has brought you coverage of study findings presented virtually this year at the American Heart Association's annual Scientific Sessions. Here is a compilation of our coverage, showing the summary's title, the title of the meeting presentation, and the published article's first author in parentheses. (Your NEJM Journal Watch subscription is required.)
Early Invasive Intervention for Atrial Fibrillation (Andrade J et al.)
Early treatment with cryoablation bests antiarrhythmic drugs. Read the summary.
Effects of n-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in The Elderly: Results of the Omemi Trial (Kalstad AA et al.)
In older patients with a recent myocardial infarction, 1.8-g omega-3 polyunsaturated fatty acid supplementation did not improve cardiovascular outcomes. Read the summary.
STRENGTH Trial: Cardiovascular Outcomes with Omega-3 Carboxylic Acids (Epanova) in Patients with High Vascular Risk and Atherogenic Dyslipidemia (Nicholls SJ et al.)
An omega-3 formulation of eicosapentaenoic acid and docosahexaenoic acid was not associated with a reduction in cardiovascular events in high-risk patients. Read the summary.
A Three-Arm N-of-1 Trial with Statin, Placebo, and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial (Wood FA et al.)
Side effects can often be provoked by placebo tablets. Read the summary.
Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention: The ALPHEUS Trial (Silvain J et al.)
Despite its greater platelet inhibition, ticagrelor was no better than clopidogrel in preventing myocardial necrosis or improving clinical outcomes. Read the summary.
Rivaroxaban Versus Warfarin in Patients with Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results from the RIVER Randomized Trial (Guimarães HP et al.)
The RIVER trial supports use of rivaroxaban as a safe, effective alternative to warfarin in this patient population. Read the summary.
A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3 (Yusuf S et al.)
A polypill plus aspirin could become part of a comprehensive strategy for the prevention of cardiovascular disease. Read the summary.
Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial (Teerlink JR et al.)
Omecamtiv mecarbil modestly improved outcomes in a placebo-controlled, randomized trial. Read the summary.
Ferric Carboxymaltose in Iron Deficient Patients Admitted for Acute Heart Failure (Ponikowski P et al.)
Intravenous ferric carboxymaltose reduced the hospitalization burden in stabilized, iron-deficient patients who had acute HF with reduced ejection fraction in a placebo-controlled, randomized trial. Read the summary.
Advanced Reperfusion Strategies for Refractory Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: The ARREST Trial (Yannopoulos D et al.)
Veno-arterial extracorporeal membrane oxygenation improved survival to hospital discharge, compared with standard advanced cardiac life support, in a small, randomized trial. Read the summary.
RHAPSODY: Rilonacept an IL-1α and IL-1β Trap Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis (Klein AL et al.)
The interleukin-1 trap rilonacept rapidly resolved recurrent pericarditis episodes and was associated with significantly lower risk for recurrence, compared with placebo. Read the summary.
SOLOIST-WHF: Sotagliflozin in Diabetes Patients with Recent Worsening Heart Failure (Bhatt DL et al.)
SCORED: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (Bhatt DL et al.)
The SGLT-2 inhibitor sotagliflozin reduced deaths from cardiovascular causes, hospitalizations, and urgent care visits, compared with placebo, without major safety issues. Read the summary.
The Efficacy and Safety of Evinacumab in Patients with Refractory Hypercholesterolemia (Rosenson RS et al.)
It might help patients with refractory hypercholesterolemia achieve LDL-c goals, but data are very preliminary. Read the summary.